Intrathecal Dexmedetomidine and Acute Neuropathic Pain After Lower Limb Amputation (DEX-RCT)
Intrathecal Dexmedetomidine Reduces Acute Neuropathic Pain After Lower Limb Amputation: A Randomized Controlled Trial
This randomized controlled trial evaluated the effect of adding intrathecal dexmedetomidine (10 µg) to hyperbaric bupivacaine (11 mg) for spinal anesthesia in patients undergoing lower limb amputation. Thirty patients (ASA I-III) scheduled for elective supra- or infracondylar amputation were randomly allocated to two groups: Control Group (n=15) received hyperbaric bupivacaine 11 mg plus saline 0.9%, and Experimental Group (n=15) received hyperbaric bupivacaine 11 mg plus dexmedetomidine 10 µg. Primary outcomes were duration of motor and sensory neuraxial block and postoperative analgesia at 48 hours. As a prespecified exploratory secondary outcome, incidence of acute neuropathic pain was assessed using the DN4 screening tool at 48 hours. The study was conducted at the Hospital Regional de Alta Especialidad Dr. Juan Graham Casasús, Villahermosa, Tabasco, Mexico, from 30 September to 15 December 2025. Ethics approval was obtained from the Institutional Review Board (CEI/JGC/C02-25) prior to patient enrollment.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tabasco
-
Villahermosa, Tabasco, Mexico, 86126
- Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients scheduled for elective supra- or infracondylar lower limb amputation
- Age 18 to 65 years
- ASA physical status I-III
- Acceptance of neuraxial anesthetic technique
Exclusion Criteria:
-
Patient refusal of anesthetic procedure
- Prolonged coagulation times
- Anatomical abnormalities of the spine
- ASA IV classification
- Atrioventricular block grade 2 or 3 without pacemaker
- Neurological deterioration (Glasgow score less than 8)
- Hemodynamic instability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Group - Bupivacaine Alone
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally. Total volume 2.3 ml. |
|
Experimental: Experimental Group - Bupivacaine plus Dexmedetomidine
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally. Total volume 2.3 ml. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion Requiring Analgesic Rescue
Time Frame: 48 hours postoperatively
|
Proportion of patients requiring at least one analgesic rescue dose during the postoperative period. |
48 hours postoperatively
|
|
Duration of Motor Block
Time Frame: 48 hours postoperatively
|
Duration of motor block assessed by modified Bromage scale (0-3, higher scores indicate greater motor block). Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
|
Duration of Sensory Block
Time Frame: 48 hours postoperatively
|
Duration of sensory block assessed by Hollmen scale. Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Acute Neuropathic Pain
Time Frame: 48 hours postoperatively
|
Incidence of acute neuropathic pain assessed by DN4 screening tool (0-10, score ≥4 indicates neuropathic pain component). Reported as exploratory secondary outcome. |
48 hours postoperatively
|
|
Heart Rate
Time Frame: 4 hours postoperatively
|
Heart rate measured in beats per minute during the first 4 hours post-block. |
4 hours postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gabriel López-Ramírez, PhD, Universidad Juárez Autónoma de Tabasco
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Nervous System Diseases
- Postoperative Complications
- Pathologic Processes
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neurobehavioral Manifestations
- Perceptual Disorders
- Pain, Postoperative
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Neuralgia
- Phantom Limb
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Imidazoles
- Inorganic Chemicals
- Chlorine Compounds
- Sodium Compounds
- Chlorides
- Hydrochloric Acid
- Dexmedetomidine
- Sodium Chloride
Other Study ID Numbers
Other Study ID Numbers
- JI-PG348
- CEI/JGC/C02-25 (Other Identifier: HRAE Dr. Juan Graham Casasus)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data underlying the published results will be available from the corresponding author on reasonable request.
IPD Sharing Time Frame
Data will be available beginning 3 months after article publication and ending 5 years after publication.
IPD Sharing Access Criteria
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal, approved by the corresponding author, for the purpose of verifying the published results or conducting individual-participant-data meta-analysis. Requests should be directed to the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.